A900120 Stock Overview
CXI Healthcare Technology Group Limited engages in the manufacture and distribution of health foods.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CXI Healthcare Technology Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩115.00 |
| 52 Week High | ₩203.00 |
| 52 Week Low | ₩107.00 |
| Beta | 1.09 |
| 1 Month Change | -7.26% |
| 3 Month Change | 0% |
| 1 Year Change | -41.03% |
| 3 Year Change | -68.75% |
| 5 Year Change | -72.88% |
| Change since IPO | -96.54% |
Recent News & Updates
Shareholder Returns
| A900120 | KR Personal Products | KR Market | |
|---|---|---|---|
| 7D | 0.9% | 6.2% | -4.3% |
| 1Y | -41.0% | -14.3% | -1.0% |
Return vs Industry: A900120 underperformed the KR Personal Products industry which returned -16% over the past year.
Return vs Market: A900120 underperformed the KR Market which returned 0.6% over the past year.
Price Volatility
| A900120 volatility | |
|---|---|
| A900120 Average Weekly Movement | 7.3% |
| Personal Products Industry Average Movement | 5.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A900120 has not had significant price volatility in the past 3 months.
Volatility Over Time: A900120's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 10 | Jin Lin | www.ckhfnh.co.kr |
CXI Healthcare Technology Group Limited engages in the manufacture and distribution of health foods. It primarily offers Chinese medicine-based health supplements in capsule, tablet, drink, and tea forms. The company was formerly known as CKH Food & Health Limited and changed its name to CXI Healthcare Technology Group Limited in October 2023.
CXI Healthcare Technology Group Limited Fundamentals Summary
| A900120 fundamental statistics | |
|---|---|
| Market cap | ₩33.15b |
| Earnings (TTM) | ₩17.47b |
| Revenue (TTM) | ₩68.12b |
1.9x
P/E Ratio0.5x
P/S RatioIs A900120 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A900120 income statement (TTM) | |
|---|---|
| Revenue | ₩68.12b |
| Cost of Revenue | ₩40.57b |
| Gross Profit | ₩27.55b |
| Other Expenses | ₩10.08b |
| Earnings | ₩17.47b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 60.60 |
| Gross Margin | 40.45% |
| Net Profit Margin | 25.64% |
| Debt/Equity Ratio | 0.06% |
How did A900120 perform over the long term?
See historical performance and comparison